Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Howard Safran MD
Closed to Accrual
To determine if trastuzumab increases disease-free survival when combined with trimodality treatment (radiation plus chemotherapy followed by surgery) for patients with HER2-overexpressing esophageal adenocarcinoma
Pathologically confirmed HER2 expressing adenocarcinoma of the esophagus centrally assessed within 56 days prior to Step 2 registration; primary adenocarcinoma of the esophagus involving the mid (up to 25 cm), distal and/or esophagogastric junction.
The Current Accrual listed below reflects the total accrual to STEP 1 (HER2 screening). This study will continue to accrue until 197 cases have completed STEP 2 registration. The current accrual to RTOG 1010 - STEP 2 registration is 194 as of 9/30/2015.
Please continue to screen your patients for this very important study and we appreciate all of your efforts.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.